USPSTF recommends docs talk with high-risk women about breast cancer drugs

09/24/2013 | Reuters

The U.S. Preventive Services Task Force has released a statement recommending that physicians talk with women at high risk of developing breast cancer about drugs that might reduce their risk. Tamoxifen or raloxifene interfere with the effects of estrogen in breast tissue, but they are associated with side effects including blood clot risk.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA